三氧化二砷对鼻咽癌患者放疗增敏作用与增殖和凋亡相关蛋白关系

Relationship between Radiotherapy Enhancing Effect of Arsenic Trioxide and the Proliferation and Apoptosis of Related Protein in Nasopharyngeal Carcinoma Patients

免费下载全文查看/发表评论下载PDF阅读器

DOI：

中文关键词: 鼻咽癌三氧化二砷放射疗法 Bcl-2 Bax p53 增殖核抗原

英文关键词:nasopharyngeal carcinoma arsenic trioxide radiotherapy Bcl-2 Bax p53 proliferating cell nuclear antigen

基金项目:国家中医药管理局中医药科学技术研究专项课题(No.04-05LL10);广东省重点科技攻关项目(No.2004B30301014);广东省医学科研课题(No.A2003532,No.B2005099)

作者	单位
林英城	汕头大学医学院附属肿瘤医院
李德锐	汕头大学医学院附属肿瘤医院
林雯	汕头大学医学院附属肿瘤医院
陈创珍	汕头大学医学院附属肿瘤医院
况丽平	汕头大学医学院病理教研室
吴晓	汕头大学医学院附属肿瘤医院广东515031
洪超群	汕头大学医学院附属肿瘤医院广东515031

摘要点击次数: 1265

全文下载次数: 1

中文摘要:

目的探讨三氧化二砷(arsenic trioxide,ATO)放疗增敏对鼻咽癌增殖和凋亡相关蛋白的影响。方法将74例T1～4N0～1M0期鼻咽癌患者随机分为单纯放疗(简称放疗组)和ATO增敏组(简称增敏组),观察两组患者放射治疗40Gy时鼻咽肿瘤和颈部淋巴结消退情况。每个患者在治疗前及放疗20Gy后的24h各取材1次。免疫组化EnVision法测定增殖核抗原(PCNA)、Bcl-2、Bax和p53蛋白表达。结果放射治疗40Gy时增敏组和放疗组的鼻咽肿瘤消退率分别43.6%(17/39例)和20.0%(7/35例),差异有显著性(χ2=4.684,P=0.003);两组颈部淋巴结消退速度差异无显著性。治疗剂量为20Gy的PCNA、Bcl-2、Bax和p53蛋白表达均下调,但仅增敏组PCNA和Bax差异有显著性(Z值分别-2.449和-3.031,P值分别为0.014和0.002)。两组24例肿瘤消失患者中,PCNA、Bax和p53蛋白下调与治疗前比较,差异有显著性(Z值分别为-2.656、-2.359和-1.999;P值分别为0.008、0.018和0.046);肿瘤未消失患者中,仅PCNA下调,与治疗前比较差异有显著性(Z=-32.815,P=0.015)。结论ATO对鼻咽癌患者有放射增敏作用,其增敏机制可能通过下调PCNA及凋亡相关蛋白,抑制肿瘤增殖和诱导凋亡有关。

英文摘要:

Objective To explore the mechanism of arsenic trioxide (ATO) in enhancing radiotherapy in nasopharyngeal carcinoma (NPC) patients. Methods Seventy-four patients with NPC of T1～4N0～1M0 were randomized into two groups: 35 patients in Group A were treated with conventional radiotherapy alone, and the 39 in Group B received radiotherapy and additional administering of ATO. The regressions of nasopharyngeal lesions and cervical lymph nodes were compared between the two groups at 40 Gy of radiation was given. And biopsy of the tissue from NPC was taken before treatment and 24 h after radiation of 20 Gy to determine the expressions of proliferating cell nuclear antigen (PCNA), Bcl-2, Bax and p53 protein by immunohistochemistry. Results When irradiation for 40 Gy, the completely regression rates of nasopharyngeal lesion were 20.0%(7/35)in Group A and 43.6%(17/39) in Group B, showing significant difference between them (χ2=4.684, P=0.003), but no significant difference was shown between the two groups in regression rate of cervical lymph node. Expression of PCNA, Bax, Bcl-2 and p53 protein was reduced in both groups, but significant difference only showed between pre- and post-treatment in PCNA (Z=-2.449,P=0.014) and Bax protein (Z=-3.031,P=0.002) in Group B. Significantly reduction of PCNA (Z=-2.656,P=0.008), Bax (Z=-2.359, P=0.018) and p53 protein (Z=-1.999,P=0.046) in patients with complete tumor regression at radiation for 20 Gy, while in those with no complete tumor regression only PCNA showed significant reduction (Z=-32.815,P=0.015). Conclusion ATO shows effect in enhancing radiotherapy on NPC patients, its mechanism might be associated with the down-regulation of PCNA and apoptosis related protein and the inhibition on tumor proliferation and apoptosis inducing.

关闭